Abbonarsi

Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION - 17/12/18

Doi : 10.1016/j.ahj.2018.06.017 
Marat Fudim, MD a, b, , Christopher M. O'Connor, MD c, Hillary Mulder, MS b, Adrian Coles, PhD b, Ankeet S. Bhatt, MD a, Andrew P. Ambrosy, MD a, b, William E. Kraus, MD a, d, Ileana L. Piña, MD, MPH e, David J. Whellan, MD f, Robert J. Mentz, MD a, b
a Duke University Medical Center, Durham, NC 
b Duke Clinical Research Institute, Durham, NC 
c Inova Heart and Vascular Institute, Fairfax, VA 
d Duke Molecular Physiology Institute, Duke University School of Medicine, Duke, NC 
e Albert Einstein, College of Medicine, New York, NY 
f Thomas Jefferson University, Philadelphia, PA 

Reprint requests: Marat Fudim, MD, Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute.Division of CardiologyDuke University Medical Center, Duke Clinical Research Institute

Abstract

Background

The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF.

Methods

HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35% to aerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively.

Results

A total of 2,004 (86%) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak Vo2 in adjusted analyses (all P > .05). A dose increase was associated with decrease in 6-minute walk distance (−4.25 m, SE 1.12 m, P < .001) and change in Kansas City Cardiomyopathy Questionnaire overall score (−0.56 m, SE 0.24 m, P = .02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95% CI 0.72-1.15; P = .432).

Conclusions

The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health status outcomes.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Javed Butler, MD, MPH, served as guest editor for this article.
 Conflict of Interest: M. F. is supported by American Heart Association grant 17MCPRP33460225 and National Institutes of Health T32 grant 5T32HL007101 and reports consulting fees from Axon Therapeutics and GE Healthcare. C. M. O. reports consulting fees from Novella and Amgen; ownership/partnership/principal in Biscardia, LLC; and research support from Otsuka, Roche Diagnostics, BG Medicine, Critical Diagnostics, Astellas, Gilead, GE Healthcare, and ResMed. R. J. M. receives research support from Amgen, AstraZeneca, BMS, GSK, Gilead, Novartis, Otsuka, and ResMed; and honoraria from Thoratec. All other authors declare no relevant financial disclosures.


© 2018  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 205

P. 133-141 - Novembre 2018 Ritorno al numero
Articolo precedente Articolo precedente
  • Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs
  • Leif Friberg
| Articolo seguente Articolo seguente
  • Impact of rotor ablation in non-paroxysmal AF patients: Findings from the per-protocol population of the OASIS trial at long-term follow-up
  • Sanghamitra Mohanty, Carola Gianni, Chintan Trivedi, Tamara Metz, Rong Bai, Amin Al-Ahmad, Shane Bailey, John David Burkhardt, G. Joseph Gallinghouse, Rodney Horton, Patrick M. Hranitzky, Javier E. Sanchez, Luigi Di Biase, Andrea Natale

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.